机构：[1]Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, PR China[2]Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, PR China四川大学华西医院[3]Department of Biology Treatment, Tianjin Oncology Hospital, Tianjin, PR China[4]Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, Jilin Province, PR China[5]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, PR China[6]Pfizer Oncology, San Diego, CA, USA[7]Pfizer Oncology Medical Affairs, Shanghai, PR China
Efficacy/safety of first-line axitinib in Asian patients with metastatic renal cell carcinoma.
Patients were assigned (2:1) to 5-mg axitinib (n = 48) or 400-mg sorafenib (n = 24) twice daily. Primary end point was progression-free survival. Objective response rate, overall survival and adverse events were also assessed.
For axitinib versus sorafenib, hazard ratio for progression-free survival was 0.652 (95% CI: 0.340-1.252; p = 0.0989), objective response rate was higher (35.4 vs 16.7%; p = 0.0495), overall survival longer (hazard ratio: 0.739; 95% CI: 0.397-1.375; p = 0.1683). Palmar-plantar erythrodysesthesia (57.4%), diarrhea (55.3%), hypertension (51.1%) were commonest adverse events with axitinib; palmar-plantar erythrodysesthesia (50.0%) with sorafenib.
Axitinib improved efficacy in Asian patients with metastatic renal cell carcinoma; adverse events were consistent with previous findings.
基金：
This study is sponsored by Pfizer Inc. Medical writing support was provided by V Dror of Engage Scientific Solutions, and funded by Pfizer
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, PR China
通讯作者：
推荐引用方式(GB/T 7714)：
Sheng Xinan,Bi Feng,Ren Xiubao,et al.First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.[J].Future oncology (London, England).2019,15(1):53-63.doi:10.2217/fon-2018-0442.
APA：
Sheng Xinan,Bi Feng,Ren Xiubao,Cheng Ying,Wang Jinwan...&Guo Jun.(2019).First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data..Future oncology (London, England),15,(1)
MLA：
Sheng Xinan,et al."First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.".Future oncology (London, England) 15..1(2019):53-63
